Risk of Dilution for Existing Shareholders Due to the Exercise of Stock Acquisition Rights
First written in FY2017. 28 of 32 entries say "Worsened", first in FY2018-Q2. Latest entry: 2026-08-28.
Remixpoint moved to the "Worse" side of this theme in 2017, 4 years before the typical company in this theme (2021).
The whole theme swung hardest in 2017: 28 of 54 companies on the "Worse" side.
50 other companies' latest entry also says "Mitigated".
- 2026-08-28MitigatedBusiness alliance
「これにより、光通信との業務提携は予定どおり実行しつつ、本業務提携に伴う新株発行による株式の希薄化は生じません。」
光通信との業務提携に伴う新株予約権の発行を実施しないこととし、本件に起因する追加的な希薄化リスクが低減した。既存の新株予約権行使による希薄化リスク全体の終息を示すものではない。 - FY2026WorsenedAnnual report
「1 April 2025–31 March 2026 (Notes) 1 and 4 23,694,000 149,044,800 5,406 5,686 5,406 5,686」
The exercise of stock acquisition rights resulted in the additional issuance of 23,694,000 shares during the fiscal year, increasing capital stock and the capital surplus by ¥5,406 million each. The potential dilution of existing shareholders' share value and voting rights percentage increased substantially. - FY2026-H1WorsenedAnnual report
「During the interim consolidated accounting period, all of the 24th Series Stock Acquisition Rights and part of the 25th Series Stock Acquisition Rights were exercised, resulting in the issuance of 22,069,000 shares.」
The exercise of 12,500,000 shares under the 24th Series Stock Acquisition Rights and 9,450,000 shares under the 25th Series Stock Acquisition Rights, among others, resulted in the additional issuance of 22,069,000 shares during the interim period, increasing the potential dilution of existing shareholders' share value and voting rights percentage. - FY2025WorsenedAnnual report
「1 April 2024–31 March 2025 (Note) 1 2,623,000 125,350,800 269 279 269 279 Between 1 April 2025 and 14 June 2025, the exercise of stock acquisition rights increased total issued shares by 12,560,000, capital stock by ¥2,995 million and the capital surplus by ¥2,995 million.」
The exercise of stock acquisition rights resulted in the issuance of 2,623,000 shares during the fiscal year, with a further 12,560,000 shares issued by the filing date. The potential dilution of existing shareholders' share value and voting rights percentage increased substantially. - FY2024WorsenedAnnual report
「21st Series Stock Acquisition Rights Number of shares underlying the stock acquisition rights ※ 1,500,000」
The issuance of the 21st Series Stock Acquisition Rights added 1,500,000 potential shares, increasing the potential dilution of existing shareholders' share value and voting rights percentage. - FY2024-Q1WorsenedAnnual report
「20th Series Stock Acquisition Rights Number of shares underlying the stock acquisition rights ※ 1,440,000」
The 20th Series paid stock options covered 1,440,000 potential shares, adding to the potential dilution of existing shareholders' share value and voting rights percentage upon exercise of the stock acquisition rights. - FY2023-Q3WorsenedAnnual report
「During the cumulative consolidated period under review, the Group's capital stock and capital surplus each increased by ¥697 million as a result of issuing new shares upon the partial exercise of paid stock options (Stock Acquisition Rights) issued to the Company's directors, employees and others as the 11th, 14th, 17th and 19th Stock Acquisition Rights.」
The partial exercise of multiple paid stock options advanced the issuance of new shares, and the number of issued shares continued to increase in a manner that could dilute existing shareholders' share value and voting rights percentage. - FY2023-Q2WorsenedAnnual report
「1 July 2022–30 September 2022 (Note) 37,500 122,695,800 7 7,874 7 693」
The exercise of the 11th and 19th Series Stock Acquisition Rights resulted in the additional issuance of 37,500 shares during the second-quarter accounting period. The potential dilution of existing shareholders accompanying the exercise of stock acquisition rights continues to increase. - FY2023-Q1WorsenedAnnual report
「The exercise of the Eleventh, Fourteenth, Seventeenth and Nineteenth Series Stock Acquisition Rights increased the total number of issued shares by 6,127,600 and increased capital and the capital reserve by ¥686 million each.」
The exercise of the 11th, 14th, 17th and 19th Series Stock Acquisition Rights resulted in the additional issuance of 6,127,600 shares, further increasing the dilution of existing shareholders' share value and voting rights percentage. - FY2022WorsenedAnnual report
「1 April 2021–31 March 2022 (Note 1) 18,276,700 116,530,700 1,371 7,180 1,371 7,198」
The exercise of stock acquisition rights resulted in the additional issuance of 18,276,700 shares during the fiscal year. A further 5,060,000 shares were issued between 1 April and 31 May 2022, increasing the potential for dilution. - FY2022-Q3WorsenedAnnual report
「Exercise of the 18th Series Stock Acquisition Rights Number of shares delivered 10,309,300 shares」
All of the 18th Series Stock Acquisition Rights were exercised, and 10,309,300 shares were delivered. The potential dilution of existing shareholders' share value and voting rights percentage increased further. - FY2022-Q2WorsenedAnnual report
「Issuance of the 18th Series Stock Acquisition Rights ① Type and number of underlying shares 10,309,300 common shares Exercise of the 18th Series Stock Acquisition Rights Number of shares delivered 10,309,300 shares」
Following the issuance of the 18th Series Stock Acquisition Rights covering 10,309,300 shares, all the rights were exercised on 9 November 2021 and the same number of shares was delivered. The potential for dilution of existing shareholders increased further. - FY2022-Q1WorsenedAnnual report
「Number of shares underlying the stock acquisition rights 2,680,000」
The 17th Series Stock Acquisition Rights covered 2,680,000 potential shares, adding to the potential dilution of existing shareholders' share value and voting rights percentage. - FY2021WorsenedAnnual report
「1 April 2020–31 March 2021 (Note 1) 37,336,400 98,254,000 1,722 5,808 1,722 5,826」
The exercise of stock acquisition rights resulted in the additional issuance of 37,336,400 shares, bringing total issued shares at the fiscal year-end to 98,254,000 and further increasing the potential for dilution. - FY2021-Q3WorsenedAnnual report
「The exercise of the 13th Series Stock Acquisition Rights increased total issued shares by 4,770,100 shares.」
The exercise of the 13th Series Stock Acquisition Rights resulted in the additional issuance of 4,770,100 shares during the third-quarter accounting period. A further 5,972,500 shares were issued by 31 January 2021, bringing total issued shares to 94,251,000. - FY2021-Q2WorsenedAnnual report
「Between the day after the end of the second-quarter consolidated accounting period and 31 October 2020, total issued shares increased by 1,650,000 through the exercise of stock acquisition rights, bringing total issued shares to 85,158,400 as of 31 October 2020.」
The exercise of the 13th Series Stock Acquisition Rights resulted in an additional 1,650,000 shares being issued after the quarter-end, increasing total issued shares to 85,158,400. The potential dilution of existing shareholders' share value and voting rights percentage has increased further. - FY2021-Q1WorsenedAnnual report
「For the 13th Series Stock Acquisition Rights, the number of the stock acquisition right-linked bonds with adjustment provisions for the exercise price exercised during the quarter was 107,117, and the number of shares delivered upon exercise during the quarter was 10,711,700.」
The exercise of the 13th Series Stock Acquisition Rights resulted in the issuance of 10,711,700 new shares, bringing total issued shares to 71,629,300. Share issuance that could dilute existing shareholders' share value and voting rights percentage is progressing further. - FY2020WorsenedAnnual report
「Issuance of the 13th Series Stock Acquisition Rights ① Type and number of underlying shares 33,333,400 common shares」
The number of shares underlying the 13th Series Stock Acquisition Rights was 33,333,400, further increasing the potential dilution of existing shareholders' share value and voting rights percentage. - FY2020-Q3WorsenedAnnual report
「For the 12th Series Stock Acquisition Rights, the type and number of shares underlying the rights are 23,952,000 common shares. If these stock acquisition rights are exercised, new shares may be issued, potentially diluting the value of shares held by existing shareholders and their voting rights percentage.」
The 12th Series Stock Acquisition Rights covered 23,952,000 common shares for issuance, increasing the potential dilution of existing shareholders' share value and voting rights percentage. - FY2020-Q1WorsenedAnnual report
「The exercise of stock acquisition rights dated 24 April 2019 increased total issued shares by 2,000 shares and capital stock and the capital surplus by ¥0 million each. A third-party allotment capital increase with a payment period from 7 June to 14 June 2019 increased total issued shares by 1,408,400 shares, capital stock by ¥250 million and the capital surplus by ¥249 million.」
The exercise of stock acquisition rights and the third-party allotment capital increase increased the number of shares by a total of 1,410,400, advancing share issuance that could dilute existing shareholders. - FY2019WorsenedAnnual report
「At a Board of Directors meeting held on 22 May 2019, the company resolved to issue the 10th Series Stock Acquisition Rights through a third-party allotment and paid stock options (stock acquisition rights) for directors and employees of the Group. Payment for the 10th Series Stock Acquisition Rights was completed on 7 June 2019. If these stock acquisition rights are exercised, new shares may be issued, potentially diluting the value of shares held by existing shareholders and their voting rights percentage.」
The issuance and payment for the 10th Series Stock Acquisition Rights and paid stock options progressed, increasing the potential for dilution from future share issuance. - FY2019-Q3WorsenedAnnual report
「1 October 2018–31 December 2018 (Note) 1,000 57,057,200 0 3,696 0 3,715 (Note) Increase resulting from the exercise of stock acquisition rights.」
The issuance of 1,000 new shares through the exercise of stock acquisition rights also occurred in the third-quarter accounting period, and the number of shares continued to increase in a manner that could dilute existing shareholders. - FY2019-Q2WorsenedAnnual report
「1 July 2018–30 September 2018 (Note) 6,000 57,056,200 0 3,695 0 3,715 (Note) Resulting from the exercise of stock acquisition rights.」
The issuance of 6,000 new shares through the exercise of stock acquisition rights also occurred in the second-quarter accounting period, and the exercise of potential shares and increase in issued shares continued. - FY2019-Q1WorsenedAnnual report
「1 April 2018–30 June 2018 (Note) 103,100 57,050,200 10 3,695 10 3,714 (Note) Resulting from the exercise of stock acquisition rights.」
The issuance of 103,100 new shares through the exercise of stock acquisition rights also occurred in the first quarter, and the number of issued shares continued to increase in a manner that could lead to dilution. - FY2018WorsenedAnnual report
「During the fiscal year, the exercise of stock acquisition rights increased the total number of issued shares by 16,991,500 and increased capital and the capital reserve by ¥3,136.622 million each.」
The issuance of new shares through the exercise of the 8th and 9th Series Stock Acquisition Rights and others progressed substantially during the fiscal year, and the number of shares continued to increase in a manner that could dilute existing shareholders. - FY2018-Q3WorsenedAnnual report
「New shares were issued because EVO FUND, the allottee of the Ninth Series Stock Acquisition Rights issued pursuant to the Board resolution of 3 October 2017, and Sea Otter Global Ventures, LLC, a partial transferee, exercised part of those rights. As a result, capital and the capital reserve each increased by ¥1,770.925 million.」
The partial exercise of the 9th Series Stock Acquisition Rights resulted in the actual issuance of 5,200,000 new shares, further increasing the number of issued shares in a manner that could dilute existing shareholders. - FY2018-Q2WorsenedAnnual report
「During the six-month period of the current consolidated fiscal year, new shares were issued as United Asia Hong Kong Group Limited and k-style investment partners Co., Ltd., the allottees of the 8th Series Stock Acquisition Rights issued pursuant to a resolution of the Board of Directors dated 23 June 2016, exercised part of those stock acquisition rights. As a result, capital stock and the capital surplus each increased by ¥1,031.050 million. In addition, the exercise of part of the paid stock options (stock acquisition rights) issued to the company's directors, employees and others pursuant to the same Board resolution increased capital stock and the capital surplus by ¥96.362 million each.」
The issuance of new shares through the exercise of the 8th Series Stock Acquisition Rights and paid stock options progressed further, increasing capital stock and the capital surplus. The risk of dilution of existing shareholders accompanying the exercise of stock acquisition rights has increased. - FY2018-Q1MaterialisedAnnual report
「In the first quarter, new shares were issued following the partial exercise of the Eighth Series Stock Acquisition Rights by United Asia Hong Kong Group Limited and 株式会社k-style investment partners, the allottees of those rights. As a result, capital and the capital reserve each increased by ¥597.290 million.」
The exercise of stock acquisition rights resulted in the issuance of 5,846,900 shares during the quarter, leading to actual share issuance that could dilute existing shareholders. A further 1,161,000 shares were issued in July. - FY2017First statedAnnual report
「At the end of the current consolidated fiscal year, the number of potential shares represented by the 8th Series Stock Acquisition Rights and paid stock options (stock acquisition rights) totaled 11,183,100 shares, equivalent to 28.0% of the 39,955,600 issued shares at the end of the current consolidated fiscal year. If these stock acquisition rights are exercised, new shares may be issued, potentially diluting the value of shares held by existing shareholders and their voting rights percentage.」
The company disclosed that potential shares totaling 11,183,100 shares, equivalent to 28.0% of total issued shares, pose a risk of dilution of share value and voting rights percentages upon exercise.